Health-related quality of life (HRQoL) in patients (pts) with progressive, poorly differentiated, extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC) enrolled in NET-02: A phase II trial of liposomal irinotecan (nal-IRI)/5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy
Authors
Craig, Z.Swain, J.
Sharma, R.
Faluyi, O. O.
Wadsley, J.
Morgan, C.
Wall, L. R.
Chau, I.
Reed, N. S.
Sarker, D.
Margetts, J.
Krell, D.
Cave, J.
Sharmila, S.
Anthoney, A.
Patel, A.
Lamarca, Angela
Hubner, Richard A
Valle, Juan W
McNamara, Mairead G
Affiliation
Leeds Institute of Clinical Trials Research, University of Leeds, LeedsIssue Date
2022
Metadata
Show full item recordCitation
Craig Z, Swain J, Sharma R, Faluyi OO, Wadsley J, Morgan C, et al. Health-related quality of life (HRQoL) in patients (pts) with progressive, poorly differentiated, extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC) enrolled in NET-02: A phase II trial of liposomal irinotecan (nal-IRI)/5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy. Journal of Clinical Oncology. 2022 Oct;40(28):293-. PubMed PMID: WOS:000891944700291.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2022.40.28_suppl.293Additional Links
https://dx.doi.org/10.1200/JCO.2022.40.28_suppl.293Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2022.40.28_suppl.293